Evaluating patient satisfaction with home immunotherapy for cancer
A French Non-interventional Prospective Multicenter Study Evaluating Quality of Care Perception of Cancer Patients Treated by Immunotherapy at Home - SATISFACT-HOME
This study is trying to see if people with advanced solid tumors are happier with their cancer immunotherapy when they receive it at home instead of in a hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | immunotherapy |
| Locations | 3 sites (Chambéry and 2 other locations) |
| Trial ID | NCT06163053 on ClinicalTrials.gov |
What this trial studies
This observational study in France aims to assess changes in patient satisfaction among individuals with solid tumors who have transitioned from receiving immunotherapy in a hospital outpatient setting to receiving it at home. Participants will include adults who have been treated with immune checkpoint inhibitors for advanced solid tumors and have been deemed eligible for home treatment by their oncology specialists. The study will collect data on patient experiences and satisfaction levels to understand the impact of this transition on their care.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced solid tumors receiving immunotherapy who have been approved for home treatment.
Not a fit: Patients who are under guardianship or participating in other interventional studies for cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life for cancer patients by improving their treatment experience at home.
How similar studies have performed: While this approach is observational, similar studies evaluating patient satisfaction with home-based treatments have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥ 18 years old * Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France * Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission * Participants who provide oral informed consent to participate in the study Exclusion Criteria: * Participants who have expressed an opposition to their data collection * Participants under guardianship * Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
Where this trial is running
Chambéry and 2 other locations
- CH Metropole Savoie — Chambéry, France (Recruiting)
- CH Francois Quesnay — Mantes-La-Jolie, France (Recruiting)
- CH de Pau — Pau, France (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.